Skip to main content
. 2020 Mar 26;45(6):1661–1672. doi: 10.3892/ijmm.2020.4553

Figure 2.

Figure 2

Effect of dinaciclib on the viability and cell cycle distribution of MM cells in vitro. (A) Multiple MM cell lines, (B) MM cells from MM patients including relapsed patients and (C) BMMCs from healthy donors were treated with dinaciclib at different concentrations for 24 h, followed by measurement of cell viability with MTT assay. (D) RPMI8226 and H929 cells were treated with dinaciclib for 24 h and DNA content of cells was analyzed by flow cytometry. (E) RPMI8226 and H929 cells were treated with dinaciclib for 24 h; protein lysates were subjected to immunoblotting with the indicated antibodies. MM, multiple myeloma; BMMCs, bone marrow mononuclear cells.